Oncology Business Management | Specialty

Evolutionary Medicine May Provide Clues for Cancer Genetics

June 28th 2019

Today, with the routine performance of single gene or germline panel testing, as well as a critical focus on prospective follow-up of individuals with incompletely understood germline variants, clinicians are developing an increasingly robust appreciation for the influence of an individual’s genetic background on the likelihood of developing specific malignancies or a group of malignant conditions.

Experts Highlight Ongoing Research Efforts Across Tumor Types

June 28th 2019

OncLive interviewed experts at the State of the Science Summits in June 2019 on research being conducted at their respective institutions.

Clinics Strive to Improve Revenue and Patient Care Amid a Growing "Cost Consciousness"

June 26th 2019

Growing awareness is prompting a revolution in vigilance and attention to detail that has significance both for the quality of care and financial health of practices.

Pfizer Acquires Array BioPharma in $11.4 Billion Deal

June 18th 2019

Pfizer Inc. has entered into a definitive merger agreement with Array BioPharma, in which Pfizer will acquire Array BioPharma for $48 per share in cash, leading to a total enterprise value of an estimated $11.4 billion.

Vaccine Opponents Haven't Looked at the Evidence

June 11th 2019

It may be difficult for many who have not lived through an outbreak to appreciate how critical it is to never permit the disease to reappear.

Oncology Community Remembers Legendary Researcher Henry T. Lynch

June 6th 2019

Henry T. Lynch, MD, the Charles F. and Mary C. Heider Endowed Chair in Cancer Research at Creighton University and a 2019 Giants of Cancer Care® award winner known by many as the “father of cancer genetics,” died June 2 at the age of 91.

Evolutions in the Treatment of EGFR-Mutated NSCLC

June 4th 2019

Sequencing With Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Second- and Third-Generation TKIs in EGFR-Mutated NSCLC

June 4th 2019

Treating With Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Resistance to Osimertinib in EGFR-Mutated NSCLC

June 4th 2019

Osimertinib in Advanced EGFR T790M-Mutant NSCLC

June 4th 2019

ASCO 2019: Oncology Leaders Select Top Studies

May 29th 2019

Within the week, thousands of abstracts spanning a multitude of tumor types will be presented at the 2019 ASCO Annual Meeting, many of which will lead to practice-changing implications for oncologists.

OncLive Honors 15 Trailblazers With Giants of Cancer Care Program

May 28th 2019

Fifteen world-renowned leaders in hematology and oncology whose research has improved and extended the lives of millions of patients make up the 2019 class of Giants of Cancer Care® award winners.

NCCN Goes Global With Guidelines Tailored for Treatment Capabilities Abroad

May 20th 2019

The NCCN is working to develop modified guidelines for specific regions that offer less-costly and less–technologically intensive cancer treatment alternatives.

Sometimes the Weight of Tradition Is Heavier Than Gold-Standard Evidence in Oncology

May 18th 2019

Evidence generated from the randomized study design may be largely ignored by an individual or a community of physicians if the results or strategies being examined do not align with existing beliefs or bias, local practice and referral patterns, and other potentially highly relevant factors unrelated to the trial outcome.

Proton Therapy: A Path to Improved Outcomes and Quality of Life

May 17th 2019

Although development outlays with proton therapy have decreased, treatment costs remain higher than for conventional radiotherapy, fueling a debate about whether the benefits justify the costs.

Primary Care Physicians' Frustrations Mirror Those of Oncologists

May 12th 2019

In 2018, primary care physicians faced many of the same challenges as oncologists, according to the 90th Annual Physician Report from Medical Economics.

When the Quality of Evidence Just Doesn't Make the Grade in Cancer Care

May 10th 2019

The oncology clinical and research communities should demand that essential clinical trials and objectively valid evidence for efficacy and toxicity be obtained and reported before any regulatory agencies or national/international cancer societies support this strategy as a “standard of care” for cancer pain management.

Future Directions in Advanced Ovarian Cancer Management

April 29th 2019